louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04860193: Audio Vestibular Functions in COVID 19 Patients in Sohag Governate
Official title: Audiovestibular Functions in Covid 19 Patients in Sohag Governate
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID19
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2021-04-26
Enrollment: 150
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The present study will include 100 of randomly selected patients who were had been confirmed to be infection with COVID 19 virus, age ranged from 20-50 years. The investigation will be done three months after infection and after being sure that the patient become noninfectious.

Brief summary: There is evidence that up to 30% of COVID-19 patients was reported with neurological manifestations such as impaired consciousness, headache, and dizziness have been reported in COVID-19 patients in addition, olfactory and taste alterations are common symptoms in patients affected by COVID-19.This study will be conducted to evaluate the effect of the novel coronavirus on audio-vestibular functions in confirmed COVID19 patients.


Eligibility criteria: Inclusion Criteria:

- Well educated patients Age: range between 20 to 50 years No previous history of hearing loss or otoneurologic disease

Well confirmed COVID 19 patients:

patients who were diagnosed with coronavirus from

* symptoms: fever, cough, generalized malaise, dyspnea.
* Laboratory finding: abnormalities have been observed in Complete blood count (CBC), high C-reactive protein and ferritin, elevated D-dimer.
* Imaging: Chest CT scan: bilateral ground glass opacities, crazy paving, and consolidation.
* nasopharyngeal swab for SARS-CoV-2 polymerase chain reaction testing (RT-PCR).

Exclusion Criteria:

* previous history of hearing loss or otoneurological disease

Primary outcomes:
measure: Basic audiological evaluation:
timeFrame: 3 months after infection
measure: Basic audiological evaluation:
timeFrame: 3 months after infection
measure: Basic audiological evaluation:
timeFrame: 3 months after infection
measure: Auditory evoked potentials:
timeFrame: 3 months after infection
measure: Auditory evoked potentials
timeFrame: 3 months after infection
measure: Effect on vestibular functions
timeFrame: 3 months after infection
measure: Effect on vestibular functions
timeFrame: 3 months after infection
measure: Effect on vestibular functions
timeFrame: 3 months after infection
measure: Effect on vestibular functions
timeFrame: 3 months after infection
Secondary outcomes:
measure: Effect on cognitive functions
timeFrame: 3 months after infection
measure: Vestibular questionnaire
timeFrame: 3 months after infection
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag faculty of medicine
Study officials:
name: Yasmeen Mohamed
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02544893: Postoperative Analgesic Effects of Using Dexmedetomidine for Ultrasound Guided Thoracic Paravertebral Block
Official title: Postoperative Analgesic Effects of Using Bupivacaine Alone or Added Dexmedetomidine for Ultrasound Guided Thoracic Paravertebral Block in Thoracotomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain
Lead sponsor: TC Erciyes University
Sponsor class: OTHER
First posted: 2015-09-09
Enrollment: 93
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: we aimed postoperative analgesic effects of using bupivacaine alone or added dexmedetomidine for ultrasound guided thoracic paravertebral block in thoracotomy

Detailed description: paravertebral block is commonly used in the treatment for acute and chronic pain.The duration of paravertebral block could theoretically be prolonged with neurolytic agents. Dexmedetomidine ,an alfa-2 adrenoreceptor agonist, is being used and adjuvant capable of prolonging duration of sensory and motor block on nerve blocks.

Eligibility criteria: Inclusion Criteria:

* ASA 1-2
* 18-65 aged
* patient undergoing thoracotomy

Exclusion Criteria:

* chronic opioid consumption
* bupivacaine and dexmedetomidine allergies
* coagulopathy
* infection at the needle insertion side
* chronic liver and kidney disease

Primary outcomes:
measure: opioid consumption
timeFrame: postoperative 24 hours
Secondary outcomes:
measure: visual analog scale
timeFrame: postoperative 1 day
Other outcomes:
Locations:
city: Kayseri
country: Turkey
facility: Erciyes University Medicine Faculty
Study officials:
affiliation: TC Erciyes University
name: esra n ünalan, resident
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06157593: Neurally Adjusted Ventilatory Assist for Weaning From Invasive Mechanical Ventilation in Critically Ill Children
Official title: Neurally Adjusted Ventilatory Assist for Weaning From Invasive Mechanical Ventilation in Critically Ill Children: A Randomised Control Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Mechanical Ventilator Weaning
Critically Ill
Mechanical Ventilation
Neurally Adjusted Ventilatory Assist
Lead sponsor: Chulalongkorn University
Sponsor class: OTHER
First posted: 2023-12-06
Enrollment: 60
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The goal of this clinical trial is to compare weaning from mechanical ventilation in critically ill children. The main questions it aims to answer are:

* Will weaning with neurally adjusted ventilatory assist (NAVA) mode ventilation result in shorter ventilator day than synchronised intermittent mandatory ventilation (SIMV) mode?
* Will weaning with NAVA mode ventilation result in shorter paediatric intensive care unit (PICU) length of stay than SIMV mode? Participants will be randomised to NAVA or SIMV group for weaning from mechanical ventilation, then PICU outcomes from both groups will be collected, analysed and compared.


Eligibility criteria: Inclusion Criteria:

* all critically ill children admitted to PICU

Exclusion Criteria:

* failure to obtain informed consent

Primary outcomes:
measure: ventilator day
timeFrame: immediately after extubation
measure: PICU length of stay
timeFrame: immediately after PICU discharge
Secondary outcomes:
measure: asynchrony index
timeFrame: 20-minute period randomly captured from the day of extubation
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Chulalongkorn University
Study officials:
References:
Clinical trial NCT01486693: Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis
Official title: Clinical Outcomes of Topical Ganciclovir Treatment in Cytomegalovirus Anterior Uveitis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Anterior Uveitis
Keywords: cytomegalovirus
uveitis
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2011-12-06
Enrollment: 60
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 40 men, 20 women, aged 40-80 years old

Brief summary: The purpose of this study was to evaluate long term efficacy and safety of topical ganciclovir treatment in Cytomegalovirus (CMV) anterior uveitis.

Detailed description: The investigators will enroll 60 patients with positive results of the CMV PCR (polymerase chain reaction) from aqueous humor tapping from January 2006 to June 2011. All the patients (40 men, 20 women) were immunocompetent and diagnosed as symptomatic CMV infection. Their medical records will be reviewed, including demographic data as well as their ophthalmic and medical histories.

The purpose of this study was to evaluate long term efficacy and safety of topical ganciclovir treatment in CMV anterior uveitis.

Eligibility criteria: Inclusion Criteria:

* Patients with positive results of the CMV PCR (polymerase chain reaction) from aqueous humor tapping. All the patients were immunocompetent and diagnosed as symptomatic CMV infection.

Exclusion Criteria:

* Patients without positive results of the CMV PCR
* Immunocompromised patients with positive results of the CMV PCR

Primary outcomes:
measure: Anterior chamber inflammation
timeFrame: 4 weeks after starting treatment
Secondary outcomes:
measure: probability of relapse-free
timeFrame: 2 years after treatment
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: I-Jong Wang, M.D PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Koizumi N, Suzuki T, Uno T, Chihara H, Shiraishi A, Hara Y, Inatomi T, Sotozono C, Kawasaki S, Yamasaki K, Mochida C, Ohashi Y, Kinoshita S. Cytomegalovirus as an etiologic factor in corneal endotheliitis. Ophthalmology. 2008 Feb;115(2):292-297.e3. doi: 10.1016/j.ophtha.2007.04.053. Epub 2007 Jul 31.
citation: Chee SP, Jap A. Cytomegalovirus anterior uveitis: outcome of treatment. Br J Ophthalmol. 2010 Dec;94(12):1648-52. doi: 10.1136/bjo.2009.167767. Epub 2010 Jun 24.
citation: van Boxtel LA, van der Lelij A, van der Meer J, Los LI. Cytomegalovirus as a cause of anterior uveitis in immunocompetent patients. Ophthalmology. 2007 Jul;114(7):1358-62. doi: 10.1016/j.ophtha.2006.09.035. Epub 2007 Feb 12.
Clinical trial NCT06151093: The Effect of Balance Exercises on Cognitive Function
Official title: Investigating the Effects of Video-Based Balance Games and Balance Exercises on Visual-Spatial Attention With EEG Brain Oscillations
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: EEG Brain Oscillations
Balance Exercises
Lead sponsor: Istanbul Medipol University Hospital
Sponsor class: OTHER
Collaborators: name: The Scientific and Technological Research Council of Turkey
First posted: 2023-11-30
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of our study is to examine the effects of balance exercises performed in virtual and real environments on visual-spatial attention and mental rotation in healthy young adult individuals using EEG brain oscillations.


Eligibility criteria: Inclusion Criteria:

* There wouldn't be any neurological conditions
* There wouldn't be drug use such as psychiatric drug
* There wouldn't be lower extremity surgery
* There wouldn't be epilepsy
* Be healthy
* Take minimum 68 points of System Usability Scale

Exclusion Criteria:

* Neurologic disorder
* Epilepsy
* Active sport life
* Colour blindness

Primary outcomes:
measure: EEG - event related oscillations
timeFrame: Baseline-6 week
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Medipol University
state: Beykoz
Study officials:
affiliation: Medipol University
name: Bahar Güntekin, Prof. Dr.
role: STUDY_DIRECTOR
References:
Clinical trial NCT02535793: Characterisation of Occupational Allergy to Drosophila
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Drosophila
Clinical Symptoms
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2015-08-31
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 68
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Allergy is a very common problem and can be a handicap in everyday life, specially when symptoms occur at work place. Some persons working with drosophila developed respiratory symptoms. Investigators tried to analyze if these manifestations could be due to a specific allergy to drosophila.

Detailed description: To do so, investigators invited laboratory workers who presented any symptoms in presence of drosophila to undergo skin prick tests in order to determine if a specific sensibilization to drosophila exists. Then, a blood sample is taken from these persons to research specific IgE directed against drosophila. By this way, investigators hope determine if a specific allergy to drosophila exists, its characteristics as prevalence, symptoms, populations concerned...in order to better protect laboratory workers and prevent allergy incidence.

Eligibility criteria: Inclusion Criteria:

* major males or females (aged \<68) who work in laboratory with drosophila in Montpellier (France)
* clinical symptoms in presence of drosophila
* The subject must be affiliated to a social security scheme
* Provision of informed consent prior to any study specific procedures

Exclusion Criteria:

* The patient has indicated against (or incompatible drug combination) concerning the implementation of a prick test
* antihistamine cure in progress
* Inability to understand the nature and goals of the study and / or communication difficulties with the investigator
* No affiliation to a French social security recipient or not such a scheme
* Major protected by law (guardianship, curator or under judicial protection)
* deprivation of liberty by judicial or administrative decision
* Increased likelihood of non compliance to the protocol or abandonment under study
* pregnancy or breastfeeding

Primary outcomes:
measure: Number of participants with positive prick test to drosophila
timeFrame: The day of inclusion
Secondary outcomes:
measure: Survey to analyse risk factors for allergy to drosophila
timeFrame: The day of inclusion
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Hôpital Arnaud de Villeneuve
Study officials:
References:
Clinical trial NCT00655993: Effect of Statin Therapy on C-reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)
Official title: Effect of Statin Therapy on C-reactive Protein Levels in Patients With COPD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: COPD
Inflammation
Keywords: COPD
Inflammation
CRP levels
simvastatin
Lead sponsor: VA Loma Linda Health Care System
Sponsor class: FED
First posted: 2008-04-10
Enrollment: 30
Sex: ALL
Minimum age (years): 40
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Hypothesis for this pilot study is that simvastatin will lower the levels of CRP and ET-1 in COPD patients.

Detailed description: Patients with chronic obstructive lung disease (COPD) have an ongoing systemic inflammation, which can be assessed by measuring C-reactive protein (CRP). CRP is found to be a strong and independent predictor of future COPD outcomes. Statins are a class of cholesterol lowering drugs that decrease mortality from cardiovascular disease and stroke. In addition, they have anti-inflammatory, anti-thrombotic and immunomodulatory properties. Statins lower C-reactive protein by the ability to reduce the production of interleukin (IL)-6, the cytokine that activates the acute phase CRP response.

Thus the rationale for this study is to evaluate effect of statins on the levels of CRP and ET-1 in COPD patients.

Eligibility criteria: Inclusion Criteria:

* Medically optimized COPD patients
* Age 40-79 years.
* serum CRP levels \>3mg/l

Exclusion Criteria:

* Current smoker
* COPD exacerbation in the last 2 months.
* Active hepatic or severe renal dysfunction.
* connective tissue disease, chronic inflammatory disease, malignancy, any acute illness, leukocytosis (\>10,000 white blood cells) or thrombocytosis (\>450,000 platelets).
* Recent h/o myocardial infarction, angina in the last 6 months.
* Pregnancy.

Primary outcomes:
measure: serum CRP levels
timeFrame: 9 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Loma Linda
country: United States
facility: VA Loma Linda Health Care System
state: California
Study officials:
affiliation: VA Loma Linda Health Care System
name: Lennard Specht, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: VA Loma LInda Healthcare System
name: Hemal J. Parekh, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: VA Loma Linda Healthcare System
name: James D. Anholm, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04969393: Effects of High Intensity Laser on Mechanical and Physiological Findings in Pregnant Women With Carpal Tunnel Syndrome
Official title: Effects of High Intensity Laser on Mechanical and Physiological Findings in Pregnant Women With Carpal Tunnel Syndrome: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Carpal Tunnel Syndrome
Pregnancy Related
Keywords: carpal tunnel syndrome
high intensity laser therapy
electrophysiology
pregnant women
Lead sponsor: October 6 University
Sponsor class: OTHER
First posted: 2021-07-20
Enrollment: 54
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will propose a novel approach to treat pregnant women with mild to moderate carpal tunnel syndrome (CTS) using the recently introduced High intensity laser therapy with its deep penetration and high-power characteristics. It's hopeful that the results of this study can fill the gap of knowledge surrounding the conservative treatment options for CTS in order to help patients restore their nerve function properly and promote new ways of addressing CTS.


Eligibility criteria: Inclusion Criteria:

(1) Pregnant women with mild to moderate CTS diagnosed by a physician according to the American Association of Electrodiagnostic recent guidelines \[18\] (2) The age ranged between 20 to 40 years (3) Had positive clinical provocative tests for the CTS (Tinel test and Phalen test) and (5) Had a history of pain, paresthesia or numbness in the median nerve distribution, nocturnal pain, and night waking

Exclusion Criteria:

Patients were excluded from the study if they had cervical disc prolapse, cervical spondylosis, thoracic outlet syndrome, diabetes, gestational diabetes, cardiovascular disorders and hypertension. Patients who had carpal tunnel release surgery and patients who were diagnosed with CTS before pregnancy were also excluded from the study.

Primary outcomes:
measure: Changes in Distal latency of median nerve sensory distal latency
timeFrame: Baseline and after 5 Weeks
measure: Changes in Distal latency of median nerve motor distal latency
timeFrame: Baseline and after 5 Weeks
Secondary outcomes:
measure: Changes in hand grip strength
timeFrame: Baseline and after 5 Weeks
measure: Changes in numeric pain rating scale (NPRS)
timeFrame: Baseline and after 5 Weeks
Other outcomes:
Locations:
city: Al Ḩayy Ath Thāmin
country: Egypt
facility: October 6 University Hospital
state: Giza
Study officials:
affiliation: Cairo University
name: Abeer F Hanafy, Ph.D
role: STUDY_CHAIR
affiliation: Faculty of Physical Therapy, October 6 University
name: Radwa M Yehia, Ph.D
role: STUDY_DIRECTOR
References:
Clinical trial NCT03639493: Bioequivalence Study of CJ-30060 in Healthy Male Volunteers
Official title: An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerabillity of CJ-30060 in Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Male Subjects
Lead sponsor: HK inno.N Corporation
Sponsor class: INDUSTRY
First posted: 2018-08-21
Enrollment: 52
Sex: MALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 10/160mg, Crestor® 20mg in healthy male volunteers.

Detailed description: The purpose of this study is to compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and Exforge® 10/160mg, Crestor® 20mg in healthy male volunteers.

Eligibility criteria: Inclusion Criteria:

* Healthy males aged 20 to 45 years at screening
* BMI: 18 \~ 29.9kg/m\^2
* Body weight ≥ 50kg
* Subjects who decided to participate in the study and signed informed consent form voluntarily after receiving detailed explanation of the study and fully understanding

Exclusion Criteria:

* Subjects who had a medical history of severe cardiovascular, respiratory, hepatobiliary, renal, hematological, gastrointestinal, endocrinological, immunological, dermatological or neuropsychological disease
* Subjects who have symptoms of an acute disease within 28 days before first administration
* Subjects who have clinically significant active, chronic disease
* Subjects who fall under the criteria below in laboratory test

  * AST/ALT \> UNL (upper normal limit) x 2
  * Total bilirubin \> UNL x 1.5
  * CrCL \< 50mL/min
  * CPK \> UNL x 2.5
* Subjects with clinically significant low blood pressure at screening test (systolic blood pressure is less than 100 mmHg or diastolic blood pressure is less than 60 mmHg)
* Subjects with any positive reaction in HBs Ag, anti-HCV Ab, anti-HIV Ab, VDRL tests

Primary outcomes:
measure: Cmax of amlodipine
timeFrame: Up to 144 hours post-dose
measure: Cmax of valsartan
timeFrame: Up to 144 hours post-dose
measure: Cmax of rosuvastatin
timeFrame: Up to 144 hours post-dose
measure: AUClast of amlodipine
timeFrame: Up to 144 hours post-dose
measure: AUClast of valsartan
timeFrame: Up to 144 hours post-dose
measure: AUClast of rosuvastatin
timeFrame: Up to 144 hours post-dose
Secondary outcomes:
measure: AUCinf of amlodipine, valsaran, rosuvastatin
timeFrame: Up to 144 hours post-dose
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Korea University Anam Hospital
Study officials:
affiliation: Korea University Anam Hospital
name: Ji Young Park, PhD
role: PRINCIPAL_INVESTIGATOR
References: